Latest Content

EVERSANA president Greg Skalicky continues the conversation, providing details about the commercialization strategy.

As precision medicine shifts from promise to practice, true patient impact will depend less on standalone drugs and more on whether pharma, MedTech, and diagnostics can finally converge to build integrated systems of care.

In today’s Pharmaceutical Executive Daily, Insilico Medicine and Qilu Pharmaceuticals launch a $120 million collaboration to advance AI-driven cardiometabolic therapies, Eli Lilly enters a billion-dollar research partnership targeting hearing loss, and industry leaders examine what it takes to bring breakthrough rare disease products to patients.

The research collaboration will leverage Seamless’ recombinase technology to develop programmable treatments for hearing loss.

The collaboration with Qilu extends Insilico’s application of generative AI into cardiometabolic disease drug discovery, with both companies aiming to advance candidates from early design through development under a shared strategic framework.

The FDA's approval is based on results from the Phase III CEPHEUS study, showing deeper and more durable responses compared with standard therapy.

Immunome president and CEO Clay Siegall explains why the weeks following JP Morgan are just as important as the conference itself.

Precigen's president and CEO discusses the recent launch of Papzimeos.

Ethan Smith, therapy area director Oncology, Norstella, explores how antibody–drug conjugates are reshaping oncology, highlighting emerging challenges around treatment sequencing, safety management through real-world evidence, and differentiation as ADC pipelines become increasingly crowded.

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks

Taking a more strategic, data-driven approach to tail spend can transform procurement from a fragmented cost center into a source of compliance strength, operational efficiency, and greater supply chain confidence.

The collaboration agreement strengthens Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset.

Clay Siegall, president and CEO of Immunome, discusses what he saw investors getting excited for at the annual healthcare conference.